Open Source in Regulatory Review: nlmixr2 Developers Meet Regulators
The nlmixr2 development team, represented by Bill Denney, Lisa Hendricks, and I (Matt Fidler), recently gave a invited seminar to the FDA quantitative clinical pharmacology reviewers to discuss nlmixr2 and how open, community-built modeling tools can be helpful in regulatory settings. The conversation was constructive and forward-looking, and a clear theme emerged: anything that lets regulatory reviewers trust, reproduce, and exchange models across tools would be very useful. As we go through these reflections, I must add that these are my takeaways and are not necessarily the views of the FDA, nor are they necessarily the views of the companies or individuals represented by the nlmixr2 working group, or the R Consortium.